Ligand Pharmaceuticals (LGND) is a royalty investor in late-stage biopharma, with revenue and EPS growth driven by a robust portfolio.

With the tech sector coming under pressure many are looking for alternative investment areas. This pharma stock is an option ...

Travere Therapeutics shares crashed Tuesday as investors digested a delay for its drug, Filspari, in treating a kidney disease.

Ligand Pharmaceuticals’ topical skin infection gel Zelsuvmi is changing hands again—sort of. After Ligand last year created Pelthos Therapeutics to support the launch of Zelsuvmi, Pelthos is now ...

As of Tuesday, January 13, Ligand Pharmaceuticals Incorporated’s LGND share price has dipped by 7.83%, which has investors questioning if this is right time to buy.

This is my tenth Ligand (LGND) article, following my most recent 06/2025 "Ligand Pharmaceuticals: Attractive Royalty Model Powers Forward". In Powers Forward, I rated Ligand as a "Buy". It has since ...

JUPITER, Fla.--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today reported financial results for the three and nine months ended September 30, 2024, and provided an operating ...

LIGAND-AI is a flagship project of the Target 2035 initiative, funded by the Innovative Health Initiative, a public-private partnership (PPP) between the European Union and the European life science ...

The ability to alter proteins to refine control over binding affinity and specificity can create tailored therapeutics with reduced side effects, highly sensitive diagnostic tools, efficient ...